Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported that on August 3, 2026, its Board Compensation Committee granted non-qualified stock options to purchase an aggregate 84,000 shares of common stock to two newly hired employees under its 2022 Employment Inducement Incentive Award Plan.
The options were issued as material inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4), carry a $4.65 exercise price equal to the grant-date closing price, have a 10-year term, and vest over four years: 25% after one year and the remaining 75% in equal monthly installments over the following three years, subject to continued service.
Positive
- 84,000-share inducement options granted to support new employee hiring
- Options priced at $4.65, equal to grant-date Nasdaq closing price
- Four-year vesting schedule with 10-year term supports employee retention incentives
Negative
- Potential shareholder dilution of up to 84,000 additional shares if options are exercised
News Explained
The August 3 grant is complete as an option award, not an immediate stock issuance: it gives two new employees a conditional right to acquire 84,000 common shares, so existing ownership could be diluted only as the options vest and are exercised, subject to continued service.
Details
Market reaction after inducement grant: ZNTL +4.95% in the Aug 4 session
In the Aug 4 session, ZNTL gained 4.95%, reflecting a moderate positive market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Inducement shares
- 84,000 shares
- Aggregate options granted to two newly hired employees
- Recipients
- two employees
- Newly hired employees receiving stock options
- Exercise price
- $4.65 per share
- Equal to the closing price on the grant date
- Option term
- 10-year term
- Term of the granted stock options
- Vesting period
- four years
- Overall vesting schedule
- First-year vesting
- 25%
- Options vesting on the first anniversary
- Remaining vesting
- 75%
- Vesting in equal monthly installments thereafter
- Remaining vesting period
- three years
- Period for monthly vesting of the remaining options
Historical Context
-
Announced planned ESMO presentations of ovarian-cancer program data and trial information
-
Granted options covering 191,000 shares to two newly hired employees
-
Appointed Shannon Campbell to the board and Sarah Kelly as commercial-strategy SVP
-
Reported MUIR trial activity including 39.1% ORR and 7.3-month median PFS
-
Announced management participation in multiple May and June investor conferences
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-qualified stock options financial
nasdaq listing rule 5635(c)(4) regulatory
exercise price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on August 3, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 84,000 shares of the Company’s common stock to two (2) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.
For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.